<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312447652</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312447652</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Association study of angiotensin II type 1 receptor: A1166C (rs5186) polymorphism with coronary heart disease using systematic meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Kui</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447652">1</xref>
<xref ref-type="aff" rid="aff2-1470320312447652">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Bin</given-names></name>
<xref ref-type="aff" rid="aff3-1470320312447652">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhang</surname><given-names>Lin</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447652">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320312447652"><label>1</label>Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, PR China</aff>
<aff id="aff2-1470320312447652"><label>2</label>Department of Forensic Medicine, Zun Yi Medical College, PR China</aff>
<aff id="aff3-1470320312447652"><label>3</label>Laboratory of Molecular Translational Medicine, West China Institute of Women and Children’s Health, Key Laboratory of Obstetric &amp; Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, PR China</aff>
<author-notes>
<corresp id="corresp1-1470320312447652">Lin Zhang, Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, PR China. Email: <email>zhanglin@scu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>181</fpage>
<lpage>188</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Angiotensin II type 1 receptor (AT1R) mediates the cardiovascular actions of angiotensin II. Growing studies have revealed the underlying association between AT1R-A1166C (rs5186) polymorphism and coronary heart disease (CHD) among the East Asia population. Results from these studies remain conflicting. We conducted this meta-analysis to estimate the overall CHD risk of AT1R-A1166C polymorphism regarding the East Asia population. We searched the PubMed, Embase and China National Knowledge Infrastructure (CNKI) databases for all articles within a range of published years from 1995 to 2011. The odds ratio (OR) corresponding to the 95% confidence interval (CI) was used to assess the different associations. The statistical heterogeneity among studies was assessed with the Q-test and <italic>I</italic><sup><italic>2</italic></sup> statistics. Up to December 2011, 17 case-control studies, including 2,366 cases and 2,414 controls, were available for our study. The C allele and the AC/CC genotypes were associated with significantly increased risk of CHD (OR = 1.59, 95% CI = 1.22–2.06 for C versus A and OR = 1.57, 95% CI = 1.16–2.13 for AC/CC versus AA, respectively). Our result suggested that AT1R-A1166C polymorphism may be involved in the development of CHD.</p>
</abstract>
<kwd-group>
<kwd>Angiotensin II type 1 receptor</kwd>
<kwd>AT1R-A1166C</kwd>
<kwd>coronary heart disease</kwd>
<kwd>single nucleotide polymorphism</kwd>
<kwd>meta-analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320312447652" sec-type="intro">
<title>Introduction</title>
<p>Coronary heart disease (CHD) remains a leading cause of death and disability worldwide.<sup><xref ref-type="bibr" rid="bibr1-1470320312447652">1</xref>,<xref ref-type="bibr" rid="bibr2-1470320312447652">2</xref></sup> A recent report from the American Heart Association showed that approximately every 25 seconds, an American will have a coronary event, and approximately every minute, someone will die of one.<sup><xref ref-type="bibr" rid="bibr3-1470320312447652">3</xref></sup> The development of CHD is the result of genetic and environmental interaction. Several risk factors for CHD, including hypercholesterolemia, hypertension, smoking and diabetes mellitus have been identified by epidemiological studies. However, there are many other candidate risk factors, one of which is gene polymorphism of the rennin-angiotensin system (RAS).</p>
<p>Angiotensin II type 1 receptor (AT1R) is a G protein-coupled receptor that mediates most of the biological actions of the RAS. Classically, the angiotensin II receptor includes two subtypes: type 1 receptor and type 2 receptor.<sup><xref ref-type="bibr" rid="bibr4-1470320312447652">4</xref></sup> The AT1R gene is located on the long arm of chromosome 3 (3q21-25), composed of five exons and four introns. A1166C variant (rs5186) is located in the 3’ untranslated region, in which there is an A to C transversion. The association of this variant with cardiovascular diseases has been revealed, but the results are conflicting. Meta-analysis suggested that AT1R-A1166C polymorphism was associated with susceptibility to hypertension,<sup><xref ref-type="bibr" rid="bibr5-1470320312447652">5</xref>,<xref ref-type="bibr" rid="bibr6-1470320312447652">6</xref></sup> but not ischemic stroke.<sup><xref ref-type="bibr" rid="bibr7-1470320312447652">7</xref></sup> To date, a number of molecular epidemiological studies have been done to evaluate the association between this variant and CHD risk, but the results are still conflicting. Several studies<sup><xref ref-type="bibr" rid="bibr8-1470320312447652">8</xref><xref ref-type="bibr" rid="bibr9-1470320312447652"/>
<xref ref-type="bibr" rid="bibr10-1470320312447652"/>
<xref ref-type="bibr" rid="bibr11-1470320312447652"/>
<xref ref-type="bibr" rid="bibr12-1470320312447652"/>
<xref ref-type="bibr" rid="bibr13-1470320312447652"/>
<xref ref-type="bibr" rid="bibr14-1470320312447652"/>
<xref ref-type="bibr" rid="bibr15-1470320312447652"/>–<xref ref-type="bibr" rid="bibr16-1470320312447652">16</xref></sup> found that the C allele in AT1R-A1166C was a risk factor for CHD, but other researchers<sup><xref ref-type="bibr" rid="bibr17-1470320312447652">17</xref><xref ref-type="bibr" rid="bibr18-1470320312447652"/>
<xref ref-type="bibr" rid="bibr19-1470320312447652"/>
<xref ref-type="bibr" rid="bibr20-1470320312447652"/>
<xref ref-type="bibr" rid="bibr21-1470320312447652"/>
<xref ref-type="bibr" rid="bibr22-1470320312447652"/>
<xref ref-type="bibr" rid="bibr23-1470320312447652"/>
<xref ref-type="bibr" rid="bibr24-1470320312447652"/>
<xref ref-type="bibr" rid="bibr25-1470320312447652"/>
<xref ref-type="bibr" rid="bibr26-1470320312447652"/>
<xref ref-type="bibr" rid="bibr27-1470320312447652"/>
<xref ref-type="bibr" rid="bibr28-1470320312447652"/>–<xref ref-type="bibr" rid="bibr29-1470320312447652">29</xref></sup> found a contrasting result.</p>
<p>Considering that a single study might have been underpowered to detect the overall effects that a single mutation can have on populations with different genetic backgrounds, a quantitative synthesis of the accumulated data from different studies was deemed important to provide evidence of the association of this variant with CHD risk. So, we carried out this meta-analysis on all published case-control studies to estimate the overall CHD risk of AT1R-A1166C polymorphism in the East Asia area, to quantify heterogeneity between the individual studies as well as to investigate the existence of potential publication bias.</p>
</sec>
<sec id="section2-1470320312447652" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1470320312447652">
<title>Publication search and inclusion criteria</title>
<p>We searched the PubMed, Embase and China National Knowledge Infrastructure (CNKI) databases for all articles within a range of published years from 1995 to 2011 on the association between AT1R-A1166C polymorphism and CHD risk (last search was updated 30 December 2011). The following terms were used in this search: ‘angiotensin II type-1 receptor’ and ‘coronary heart disease or myocardial infarction’ and ‘polymorphism or polymorphisms.’ In order to identify the relevant publications, the references cited in the research papers were also scanned.</p>
<p>Studies testing the association between AT1R-A1166C polymorphism and CHD risk were included if all the following conditions were met: (a) the publication was a case-control study; (b) an evaluation of the association of AT1R-A1166C polymorphism and CHD was included; (c) the CHD diagnosis complied with the diagnosis criteria of the World Health Organization (WHO); (d) the study authors reported odds ratio (OR) data for their calculation; (e) the control subjects satisfied the Hardy-Weinberg equilibrium (HWE); and (f) the study was published in English or Chinese.</p>
</sec>
<sec id="section4-1470320312447652">
<title>Data extraction</title>
<p>Data from these studies were extracted by Kui Zhang and Bin Zhou. Publications were read by Kui Zhang in order to check original data extraction. If the studies had the same or overlapping data,<sup><xref ref-type="bibr" rid="bibr30-1470320312447652">30</xref><xref ref-type="bibr" rid="bibr31-1470320312447652"/>
<xref ref-type="bibr" rid="bibr32-1470320312447652"/>
<xref ref-type="bibr" rid="bibr33-1470320312447652"/>
<xref ref-type="bibr" rid="bibr34-1470320312447652"/>
<xref ref-type="bibr" rid="bibr35-1470320312447652"/>–<xref ref-type="bibr" rid="bibr36-1470320312447652">36</xref></sup> we selected the more recent one with a larger number of participants. Finally, the data for this meta-analysis were available from 17 case-control studies, including 2,366 cases and 2,414 controls. The following information was recorded for each study: first author, year of publication, region, number of alleles, number of genotypes, genotyping methods, matching criteria, frequencies of C allele in control subjects and evidence of HWE in control subjects (all of the data are shown in <xref ref-type="table" rid="table1-1470320312447652">Table 1</xref>).</p>
<table-wrap id="table1-1470320312447652" position="float">
<label>Table 1.</label>
<caption>
<p>Characteristics of literature included in the meta-analysis.</p>
</caption>
<graphic alternate-form-of="table1-1470320312447652" xlink:href="10.1177_1470320312447652-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Reference</th>
<th align="left">Year</th>
<th align="left">Region</th>
<th align="left" colspan="2">CHD<hr/></th>
<th align="left" colspan="2">Control<hr/></th>
<th align="left" colspan="3">CHD<hr/></th>
<th align="left" colspan="3">Control<hr/></th>
<th align="left" rowspan="2">Genotyping</th>
<th align="left" rowspan="2">Stage of CHD</th>
<th align="left" rowspan="2">Matching criteria</th>
<th align="left" rowspan="2">C allelic frequency in controls</th>
<th align="left" rowspan="2">HWE of control</th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th align="left">A</th>
<th align="left">C</th>
<th align="left">A</th>
<th align="left">C</th>
<th align="left">AA</th>
<th align="left">AC</th>
<th align="left">CC</th>
<th align="left">AA</th>
<th align="left">AC</th>
<th align="left">CC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gao L<sup><xref ref-type="table-fn" rid="table-fn1-1470320312447652">#</xref><xref ref-type="bibr" rid="bibr10-1470320312447652">10</xref></sup></td>
<td>2000</td>
<td>China (Hubei)</td>
<td>76</td>
<td>10</td>
<td>141</td>
<td>5</td>
<td>34</td>
<td>8</td>
<td>1</td>
<td>68</td>
<td>5</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Unclassified</td>
<td>Age, sex</td>
<td>0.035</td>
<td>Yes</td>
</tr>
<tr>
<td>Xiang K<sup><xref ref-type="bibr" rid="bibr11-1470320312447652">11</xref></sup></td>
<td>1998</td>
<td>China (Shanghai)</td>
<td>166</td>
<td>16</td>
<td>131</td>
<td>3</td>
<td>75</td>
<td>16</td>
<td>0</td>
<td>64</td>
<td>3</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.023</td>
<td>Yes</td>
</tr>
<tr>
<td>Fan X<sup><xref ref-type="bibr" rid="bibr20-1470320312447652">20</xref></sup></td>
<td>2004</td>
<td>China (Henan)</td>
<td>243</td>
<td>17</td>
<td>171</td>
<td>9</td>
<td>113</td>
<td>17</td>
<td>0</td>
<td>81</td>
<td>9</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Unclassified</td>
<td>Age, sex</td>
<td>0.053</td>
<td>Yes</td>
</tr>
<tr>
<td>Deng J<sup><xref ref-type="bibr" rid="bibr12-1470320312447652">12</xref></sup></td>
<td>2001</td>
<td>China (Sichuan)</td>
<td>147</td>
<td>35</td>
<td>150</td>
<td>10</td>
<td>61</td>
<td>25</td>
<td>5</td>
<td>70</td>
<td>10</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.067</td>
<td>Yes</td>
</tr>
<tr>
<td>Deng J<xref ref-type="table-fn" rid="table-fn1-1470320312447652">*</xref><sup><xref ref-type="bibr" rid="bibr12-1470320312447652">12</xref></sup></td>
<td>2001</td>
<td>China (Sichuan)</td>
<td>72</td>
<td>20</td>
<td>150</td>
<td>10</td>
<td>30</td>
<td>12</td>
<td>4</td>
<td>70</td>
<td>10</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td/>
<td>Yes</td>
</tr>
<tr>
<td>Liu C<sup><xref ref-type="bibr" rid="bibr21-1470320312447652">21</xref></sup></td>
<td>2001</td>
<td>China (Guangdong)</td>
<td>139</td>
<td>7</td>
<td>357</td>
<td>15</td>
<td>68</td>
<td>3</td>
<td>2</td>
<td>171</td>
<td>15</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.042</td>
<td>Yes</td>
</tr>
<tr>
<td>Jia Y<sup><xref ref-type="bibr" rid="bibr22-1470320312447652">22</xref></sup></td>
<td>2006</td>
<td>China (Shanxi)</td>
<td>202</td>
<td>16</td>
<td>199</td>
<td>13</td>
<td>93</td>
<td>16</td>
<td>0</td>
<td>93</td>
<td>13</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.065</td>
<td>Yes</td>
</tr>
<tr>
<td>Xu X<sup><xref ref-type="bibr" rid="bibr23-1470320312447652">23</xref></sup></td>
<td>2007</td>
<td>China (Jiangsu)</td>
<td>157</td>
<td>37</td>
<td>95</td>
<td>21</td>
<td>62</td>
<td>33</td>
<td>2</td>
<td>39</td>
<td>17</td>
<td>2</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.221</td>
<td>Yes</td>
</tr>
<tr>
<td>Xie Y<sup><xref ref-type="bibr" rid="bibr13-1470320312447652">13</xref></sup></td>
<td>2008</td>
<td>China (Xinjiang)</td>
<td>439</td>
<td>43</td>
<td>156</td>
<td>4</td>
<td>198</td>
<td>43</td>
<td>0</td>
<td>76</td>
<td>4</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Stenting</td>
<td>Age, sex, ethnicity</td>
<td>0.026</td>
<td>Yes</td>
</tr>
<tr>
<td>Liu R<sup><xref ref-type="bibr" rid="bibr24-1470320312447652">24</xref></sup></td>
<td>2002</td>
<td>China (Sichuan)</td>
<td>211</td>
<td>15</td>
<td>246</td>
<td>20</td>
<td>98</td>
<td>15</td>
<td>0</td>
<td>114</td>
<td>18</td>
<td>1</td>
<td>PCR-RFLP</td>
<td>Angina</td>
<td>Age, sex, ethnicity</td>
<td>0.081</td>
<td>Yes</td>
</tr>
<tr>
<td>Liu R<xref ref-type="table-fn" rid="table-fn1-1470320312447652">*</xref><sup><xref ref-type="bibr" rid="bibr24-1470320312447652">24</xref></sup></td>
<td>2002</td>
<td>China (Sichuan)</td>
<td>100</td>
<td>4</td>
<td>246</td>
<td>20</td>
<td>48</td>
<td>4</td>
<td>0</td>
<td>114</td>
<td>18</td>
<td>1</td>
<td>PCR-RFLP</td>
<td>Angina</td>
<td>Age, sex, ethnicity</td>
<td/>
<td>Yes</td>
</tr>
<tr>
<td>Zhang K<xref ref-type="table-fn" rid="table-fn1-1470320312447652">*</xref><sup><xref ref-type="bibr" rid="bibr25-1470320312447652">25</xref></sup></td>
<td>2005</td>
<td>China (Shanghai)</td>
<td>300</td>
<td>42</td>
<td>690</td>
<td>78</td>
<td>130</td>
<td>40</td>
<td>1</td>
<td>148</td>
<td>50</td>
<td>2</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.113</td>
<td>Yes</td>
</tr>
<tr>
<td>Zhang R<sup><xref ref-type="bibr" rid="bibr26-1470320312447652">26</xref></sup></td>
<td>2004</td>
<td>China (Guangdong)</td>
<td>187</td>
<td>17</td>
<td>283</td>
<td>13</td>
<td>86</td>
<td>15</td>
<td>1</td>
<td>135</td>
<td>13</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Unclassified</td>
<td>Age, sex</td>
<td>0.046</td>
<td>Yes</td>
</tr>
<tr>
<td>Yang T<sup><xref ref-type="bibr" rid="bibr14-1470320312447652">14</xref></sup></td>
<td>2008</td>
<td>China (Tianjin)</td>
<td>646</td>
<td>264</td>
<td>759</td>
<td>171</td>
<td>229</td>
<td>188</td>
<td>38</td>
<td>304</td>
<td>151</td>
<td>10</td>
<td>ASO-PCR</td>
<td>Unclassified</td>
<td>Age, sex</td>
<td>0.225</td>
<td>Yes</td>
</tr>
<tr>
<td>Guan L<xref ref-type="table-fn" rid="table-fn1-1470320312447652">#</xref><sup><xref ref-type="bibr" rid="bibr15-1470320312447652">15</xref></sup></td>
<td>2003</td>
<td>China (Shandong)</td>
<td>114</td>
<td>10</td>
<td>198</td>
<td>4</td>
<td>52</td>
<td>10</td>
<td>0</td>
<td>97</td>
<td>4</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>Unclassified</td>
<td>Age, sex</td>
<td>0.020</td>
<td>Yes</td>
</tr>
<tr>
<td>Yanping D<xref ref-type="table-fn" rid="table-fn1-1470320312447652">*</xref><sup><xref ref-type="bibr" rid="bibr27-1470320312447652">27</xref></sup></td>
<td>2006</td>
<td>China (Henan)</td>
<td>303</td>
<td>13</td>
<td>189</td>
<td>11</td>
<td>148</td>
<td>7</td>
<td>3</td>
<td>90</td>
<td>9</td>
<td>1</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.058</td>
<td>Yes</td>
</tr>
<tr>
<td>Peng J<sup><xref ref-type="bibr" rid="bibr28-1470320312447652">28</xref></sup></td>
<td>2002</td>
<td>China (Guangdong)</td>
<td>286</td>
<td>8</td>
<td>231</td>
<td>7</td>
<td>139</td>
<td>8</td>
<td>0</td>
<td>112</td>
<td>7</td>
<td>0</td>
<td>PCR-RFLP</td>
<td>MI</td>
<td>Age, sex</td>
<td>0.030</td>
<td>Yes</td>
</tr>
<tr>
<td>Aoki S<sup><xref ref-type="bibr" rid="bibr16-1470320312447652">16</xref></sup></td>
<td>2001</td>
<td>Japan (Tokyo)</td>
<td>270</td>
<td>30</td>
<td>290</td>
<td>10</td>
<td>120</td>
<td>30</td>
<td>0</td>
<td>141</td>
<td>8</td>
<td>1</td>
<td>PCR-RFLP</td>
<td>MI</td>
<td>Age, sex</td>
<td>0.034</td>
<td>Yes</td>
</tr>
<tr>
<td>Nakauchi Y<sup><xref ref-type="bibr" rid="bibr29-1470320312447652">29</xref></sup></td>
<td>1996</td>
<td>Japan ( Kochi)</td>
<td>251</td>
<td>15</td>
<td>474</td>
<td>42</td>
<td>118</td>
<td>15</td>
<td>0</td>
<td>217</td>
<td>40</td>
<td>1</td>
<td>PCR-RFLP</td>
<td>Angina and MI</td>
<td>Age, sex</td>
<td>0.089</td>
<td>Yes</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320312447652">
<p># patients with coronary heart disease and diabetes; * patients with coronary heart disease and hypertension; CHD: coronary heart disease;  ASO-PCR: polymerase chain reaction-allele specific oligonucleotide; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; HWE: Hardy-Weinberg Equilibrium; MI: myocardial infarction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-1470320312447652">
<title>Statistical analysis</title>
<p>The OR corresponding to the 95% confidence interval (CI) was used to assess the association between AT1R-A1166C polymorphism and risk of CHD. We evaluated the risk of the C allele on CHD compared with the A allele and then calculated the OR of AC/CC genotypes versus AA genotype using the dominant genetic model of the C allele.</p>
<p>The statistical heterogeneity among studies was assessed with the Q-test and <italic>I</italic><sup><italic>2</italic></sup> statistics.<sup><xref ref-type="bibr" rid="bibr37-1470320312447652">37</xref></sup> If there was no obvious heterogeneity, the ﬁxed-effects model (the Mantel-Haenszel method) was used to estimate the summary OR;<sup><xref ref-type="bibr" rid="bibr38-1470320312447652">38</xref></sup> otherwise, the random-effects model (the DerSimonian and Laird method) was used.<sup><xref ref-type="bibr" rid="bibr39-1470320312447652">39</xref></sup> To explore sources of heterogeneity across studies, we did logistic meta-regression analyses. We examined the following study characteristics: publication year, region, genotyping, matching criteria, number of alleles and number of genotypes. The HWE was assessed by Fisher’s exact test (significance set at <italic>p</italic>&lt;0.10). Publication bias was evaluated with funnel plot and Begg’s rank correlation method.<sup><xref ref-type="bibr" rid="bibr40-1470320312447652">40</xref></sup> The statistical analyses were performed by STATA 12.0 software (Stata Corp., College Station, TX).</p>
</sec>
</sec>
<sec id="section6-1470320312447652" sec-type="results">
<title>Results</title>
<sec id="section7-1470320312447652">
<title>Characteristics of studies</title>
<p>Overall, 17 case-control studies with 2,366 cases and 2,414 controls were available for this analysis. Among the above studies, two studies with 105 cases and 174 controls were available for diabetes sub-analysis, and four studies with 427 cases and 513 controls were available for hypertension sub-analysis. Study characteristics are summarized in <xref ref-type="table" rid="table1-1470320312447652">Table 1</xref>. The sample size in these case-control studies varied considerably (ranging from 116 to 920 individuals). Two genotyping methods were used, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and polymerase chain reaction-allele specific oligonucleotide (ASO-PCR). The genotype distributions among the controls of all studies were consistent with HWE, and those disagreeing with HWE were intentionally excluded from our research.<sup><xref ref-type="bibr" rid="bibr41-1470320312447652">41</xref></sup></p>
</sec>
<sec id="section8-1470320312447652">
<title>Quantitative synthesis</title>
<p>For control subjects, C allele frequency of AT1R-A1166C polymorphism ranged from 0.020 to 0.225. The evaluation of the association of AT1R-A1166C polymorphism with CHD risk is shown in <xref ref-type="fig" rid="fig1-1470320312447652">Figure 1</xref> and <xref ref-type="fig" rid="fig2-1470320312447652">Figure 2</xref>.</p>
<fig id="fig1-1470320312447652" position="float">
<label>Figure 1.</label>
<caption>
<p>Forest plot of CHD associated with distribution of C allelic frequency of AT1R-A1166C.</p>
<p>OR: odds ratio; CI: confidence interval.</p>
</caption>
<graphic xlink:href="10.1177_1470320312447652-fig1.tif"/>
</fig>
<fig id="fig2-1470320312447652" position="float">
<label>Figure 2.</label>
<caption>
<p>Forest plot of CHD associated with distribution of C allelic carriers of AT1R-A1166C.</p>
<p>OR: odds ratio; CI: confidence interval.</p>
</caption>
<graphic xlink:href="10.1177_1470320312447652-fig2.tif"/></fig>
<p>The C allele and the AC/CC genotypes were associated with a significantly increased risk of CHD (OR = 1.59, 95% CI = 1.22–2.06 for C versus A and OR = 1.57, 95% CI = 1.16–2.13 for AC/CC versus AA, respectively) by a random effects model. After stratiﬁed analyses, the patients who had diabetes mellitus with C allele of AT1R-A1166C polymorphism were more susceptible to CHD (OR = 3.99, 95% CI = 1.78–8.97 for C versus A and OR = 4.08, 95% CI = 1.76–9.45 for AC/CC versus AA, respectively). However, no significantly elevated risk with CHD was found in the patients with hypertension (OR = 1.22, 95% CI = 0.57–2.63 for C versus A and OR = 1.02, 95% CI = 0.47–2.25 for AC/CC versus AA, respectively).</p>
</sec>
<sec id="section9-1470320312447652">
<title>Evaluation of heterogeneity</title>
<p>There was heterogeneity among studies in overall comparisons (<italic>P</italic><sub><italic>heterogeneity</italic></sub> = 0.001, <italic>I</italic><sup><italic>2</italic></sup> = 59.2%, Tau<sup>2</sup> = 0.1516 for C versus A and <italic>P</italic><sub><italic>heterogeneity</italic></sub> = 0.000, <italic>I</italic><sup><italic>2</italic></sup> = 63.6%, Tau<sup>2</sup> = 0.2238 for AC/CC versus AA, respectively). To explore sources of heterogeneity across studies, we assessed allele comparison (C versus A) and dominant model comparison (AC/CC versus AA) by source of publication year, region, genotyping methods, matching criteria, quantity of C allele in the CHD group, quantity of A allele in the CHD group, quantity of C allele in the control group, quantity of A allele in the control group, quantity of AC/CC genotypes in the CHD group, quantity of AA genotype in the CHD group, quantity of AC/CC genotypes in the control group and quantity of AA genotype in the control group.</p>
<p>We found that quantity of C allele in the CHD group (<italic>P</italic> = 0.002 for allele comparison), quantity of C allele in the control group (<italic>P</italic> = 0.006 for allele comparison), quantity of A allele in the control group (<italic>P</italic> = 0.018 for allele comparison), quantity of AC/CC genotypes in the CHD group (<italic>P</italic> = 0.001 for dominant genetic model comparison), quantity of AC/CC genotypes in the control group (<italic>P</italic> = 0.006 for dominant genetic model comparison), but not publication year, region, genotyping methods or matching criteria (<italic>P</italic> &gt; 0.05) could substantially influence the initial heterogeneity.</p>
</sec>
<sec id="section10-1470320312447652">
<title>Sensitivity analysis</title>
<p>The influence of a single study on the overall meta-analysis estimate was investigated by omitting one study at a time, and the omission of any study made no significant difference, indicating that our results were statistically reliable.</p>
</sec>
<sec id="section11-1470320312447652">
<title>Publication bias</title>
<p>Begg’s test was performed to evaluate the publication bias of selected literatures. <xref ref-type="fig" rid="fig3-1470320312447652">Figure 3</xref> displays a funnel plot that examined the AT1R-A1166C polymorphism and overall CHD risk included in the meta-analysis.</p>
<fig id="fig3-1470320312447652" position="float">
<label>Figure 3.</label>
<caption>
<p>Begg’s funnel plot for publication bias test. Each point represents a separate study for the indicated association.</p>
<p>SE: standardized effect.</p>
</caption>
<graphic xlink:href="10.1177_1470320312447652-fig3.tif"/>
</fig>
<p>No evidence of publication bias in our study was observed (<italic>P</italic> = 0.763).</p>
</sec>
</sec>
<sec id="section12-1470320312447652" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we performed a systematic review of the association between AT1R-A1166C polymorphism and risk for CHD based on 17 case-control studies for which information was available. Our meta-analysis identified that the C allele and AC/CC genotypes had a statistically significant increased CHD risk in East Asia by a random effects model. These findings indicated that AT1R-A1166C polymorphism may play a role in CHD development.</p>
<p>AT1R mediates the cardiovascular actions of angiotensin II<sup><xref ref-type="bibr" rid="bibr42-1470320312447652">42</xref><xref ref-type="bibr" rid="bibr43-1470320312447652"/>–<xref ref-type="bibr" rid="bibr44-1470320312447652">44</xref></sup> and is a member of the G-protein-coupled receptor superfamily expressed in most tissues, where receptor activation leads to vasoconstriction, water retention and vascular smooth muscle cell proliferation and hypertrophy.<sup><xref ref-type="bibr" rid="bibr45-1470320312447652">45</xref>,<xref ref-type="bibr" rid="bibr46-1470320312447652">46</xref></sup> It can still stimulate reactive oxygen species within the cell nucleus.<sup><xref ref-type="bibr" rid="bibr47-1470320312447652">47</xref></sup> Functional studies indicate that the expression of the A allele, rather than C allele, was down regulated by miR-155. Further evidence from rodent models shows that the C allele regulated the expression of the AT1R gene by weakening the ability of miR-155.<sup><xref ref-type="bibr" rid="bibr48-1470320312447652">48</xref></sup> That may be the possible mechanism of AT1R-A1166C polymorphism involvement in the development of CHD, but further studies are needed to confirm the potential mechanism.</p>
<p>Previous meta-analysis conducted by Zhang suggests that the C allele of AT1R-A1166C polymorphism is associated with an increased risk of myocardial infarction (MI).<sup><xref ref-type="bibr" rid="bibr49-1470320312447652">49</xref></sup> Xu et al. conducted a meta-analysis, and their results suggest that AT1R-A1166C polymorphism was associated with increased CHD risk in the overall analysis. However, null result was found in the East Asia population in an analysis by geographic region.<sup><xref ref-type="bibr" rid="bibr50-1470320312447652">50</xref></sup> Our result suggests that AT1R-A1166C polymorphism may have a statistically significant increased CHD risk. Due to the relatively small size of studies available, further studies with larger participants are needed to confirm this result.</p>
<p>Stratiﬁed analyses were performed to reveal the association of CHD risk with AT1R-A1166C polymorphism in CHD patients with diabetes or hypertension. The patients who had diabetes mellitus with C allele of AT1R-A1166C polymorphism were more susceptible to CHD. Nevertheless, no significantly elevated risk with CHD was found in the patients with hypertension. The null result may be due to the limited number of studies, with only four studies available in this meta-analysis.</p>
<p>Our study evaluated the heterogeneity, and the results included the heterogeneity for C versus A (<italic>P</italic><sub><italic>heterogeneity</italic></sub> = 0.001, <italic>I</italic><sup><italic>2</italic></sup> = 59.2%, Tau<sup><xref ref-type="bibr" rid="bibr2-1470320312447652">2</xref></sup> = 0.1516) and for AC/CC versus AA (<italic>P</italic><sub><italic>heterogeneity</italic></sub> = 0.000, <italic>I</italic><sup><italic>2</italic></sup> = 63.6%, Tau<sup><xref ref-type="bibr" rid="bibr2-1470320312447652">2</xref></sup> = 0.2238). However, meta-regression analyses with the dependent variable logarithm OR found the heterogeneity was not related to the publication year, region, genotyping methods or matching criteria (<italic>P</italic> &gt; 0.05), but related to quantity of C allele in the CHD group (<italic>P</italic> = 0.002 for allele comparison), quantity of C allele in the control group (<italic>P</italic> = 0.006 for allele comparison), quantity of A allele in the control group (<italic>P</italic> = 0.018 for allele comparison), quantity of AC/CC genotypes in the CHD group (<italic>P</italic> = 0.001 for dominant genetic model comparison) and quantity of AC/CC genotypes in the control group (<italic>P</italic> = 0.006 for dominant genetic model comparison). Because only 17 case-control studies with 2,366 cases and 2,414 controls were thus far available for this analysis, further studies using large numbers of participants should be conducted to validate the association. There was no strong evidence that any single factor played an important role in explaining the heterogeneity observed. The influence of a single study on the overall meta-analysis estimate was investigated by omitting one study at a time, and the omission of any study made no significant difference, indicating that our results were statistically reliable. The Begg’s test denied the publication bias in our study (<italic>P</italic> = 0.763).</p>
<p>The data included in the present meta-analysis have some limitations: (a) all enrolled studies were case-control studies, in which cases were survivors of cardiovascular events, and those who did not survive were not included; (b) to date, only 17 studies were available for this study; the relatively small size of participants was responsible for the heterogeneity; (c) this study was conducted relating to an East Asia population, and the populations of other races were underrepresented; (d) most of the enrolled studies only included the association of AT1R-A1166C polymorphism with CHD; further studies estimating the effect of gene-gene and gene-environment interactions may eventually provide a better, comprehensive understanding; and (e) due to the low frequency of the minor allele, analysis by using any more genetic models is difficult.</p>
<p>In conclusion, this meta-analysis indicated that AT1R-A1166C polymorphism was involved in the development of CHD. However, well-designed studies with a larger sample size should be conducted to confirm this result. Moreover, further studies estimating the effect of gene-gene and gene-environment interactions may eventually provide a better, comprehensive understanding.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312447652">
<label>1.</label>
<citation citation-type="web">
<collab>The World Health Organization</collab>. <source>Cardiovascular diseases</source>, <ext-link ext-link-type="uri" xlink:href="http://www.who.int/cardiovascular_diseases/en/">http://www.who.int/cardiovascular_diseases/en/</ext-link> (<access-date>accessed December 2011</access-date>).</citation>
</ref>
<ref id="bibr2-1470320312447652">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mensah</surname><given-names>GA</given-names></name>
<name><surname>Brown</surname><given-names>DW</given-names></name>
</person-group>. <article-title>An overview of cardiovascular disease burden in the United States</article-title>. <source>Health Aff (Millwood)</source> <year>2007</year>; <volume>26</volume>: <fpage>38</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312447652">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roger</surname><given-names>VL</given-names></name>
<name><surname>Go</surname><given-names>AS</given-names></name>
<name><surname>Lloyd-Jones</surname><given-names>DM</given-names></name><etal/>
</person-group>. <article-title>Heart disease and stroke statistics—2012 update: a report from the American Heart Association</article-title>. <source>Circulation</source> <year>2012</year>; <volume>125</volume>: <fpage>e2</fpage>–<lpage>e220</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312447652">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>YC</given-names></name>
<name><surname>Zhu</surname><given-names>YZ</given-names></name>
<name><surname>Lu</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling</article-title>. <source>Clin Exp Pharmacol Physiol</source> <year>2003</year>; <volume>30</volume>: <fpage>911</fpage>–<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312447652">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>JL</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Hao</surname><given-names>PP</given-names></name><etal/>
</person-group>. <article-title>Angiotensin II type 1 receptor gene A1166C polymorphism and essential hypertension in Chinese: a meta-analysis</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2010</year>; <volume>11</volume>: <fpage>127</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312447652">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niu</surname><given-names>W</given-names></name>
<name><surname>Qi</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Association of the angiotensin II type I receptor gene +1166 A&gt;C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects</article-title>. <source>Hypertens Res</source> <year>2010</year>; <volume>33</volume>: <fpage>1137</fpage>–<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr7-1470320312447652">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Sun</surname><given-names>M</given-names></name>
<name><surname>Sun</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Association between angiotensin II type 1 receptor gene polymorphisms and ischemic stroke: a meta-analysis</article-title>. <source>Cerebrovasc Dis</source> <year>2011</year>; <volume>32</volume>: <fpage>431</fpage>–<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr8-1470320312447652">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tiret</surname><given-names>L</given-names></name>
<name><surname>Bonnardeaux</surname><given-names>A</given-names></name>
<name><surname>Poirier</surname><given-names>O</given-names></name><etal/>
</person-group>. <article-title>Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction</article-title>. <source>Lancet</source> <year>1994</year>; <volume>344</volume>: <fpage>910</fpage>–<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312447652">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez</surname><given-names>R</given-names></name>
<name><surname>Reguero</surname><given-names>JR</given-names></name>
<name><surname>Batalla</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease</article-title>. <source>Cardiovasc Res</source> <year>1998</year>; <volume>40</volume>: <fpage>375</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312447652">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname><given-names>L</given-names></name>
<name><surname>Gan</surname><given-names>PZ</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Relationship between angiotensin 2 type 1 receptor gene A1166C polymorphism and diabetes complicated with coronary heart disease</article-title>. <source>Chin J Endocrinol Metab</source> <year>2000</year>; <volume>16</volume>: <fpage>216</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr11-1470320312447652">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>K</given-names></name>
<name><surname>Zheng</surname><given-names>T</given-names></name>
<name><surname>Sun</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>The relationship between angiotensin type 1 receptor gene and coronary heart disease, hypertension and diabetes mellitus in Chinese</article-title>. <source>Chin J Med Genet</source> <year>1998</year>; <volume>15</volume>: <fpage>9</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312447652">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deng</surname><given-names>JL</given-names></name>
<name><surname>Yu</surname><given-names>HZ</given-names></name>
<name><surname>Yang</surname><given-names>Q</given-names></name>
<name><surname>et</surname><given-names>al</given-names></name>
</person-group>. <article-title>Relation between coronary artery disease and polymorphism of type 1 angiotensin receptor gene</article-title>. <source>S China J Cardiovasc Dis</source> <year>2001</year>; <volume>7</volume>: <fpage>258</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr13-1470320312447652">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xie</surname><given-names>YX</given-names></name>
<name><surname>Ma</surname><given-names>YT</given-names></name>
<name><surname>Buai</surname><given-names>JH</given-names></name><etal/>
</person-group>. <article-title>The relationship between angiotensin type 1 receptor gene and coronary heart disease, hypertension and diabetes mellitus in the Han and Uyghur people in Xinjiang</article-title>. <source>J Xinjiang Med Univ</source> <year>2008</year>; <volume>31</volume>: <fpage>1135</fpage>–<lpage>1139</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312447652">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>T</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>JZ</given-names></name>
<etal/>
</person-group>. <article-title>AngII type 1 receptor polymorphism is association with coronary artery disease</article-title>. <source>Mol Cardio China</source> <year>2008</year>; <volume>8</volume>: <fpage>91</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr15-1470320312447652">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guan</surname><given-names>LX</given-names></name>
<name><surname>Zhang</surname><given-names>YZ</given-names></name>
<name><surname>Wang</surname><given-names>JX</given-names></name><etal/>
</person-group>. <article-title>Association between the type angiotensin receptor(at1r) gene A1166C polymorphism and insulin resistance in patients with type 2 diabetes</article-title>. <source>Chinese Journal of Birth Health &amp; Heredity</source> <year>2003</year>; <volume>11</volume>: <fpage>30</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312447652">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aoki</surname><given-names>S</given-names></name>
<name><surname>Mukae</surname><given-names>S</given-names></name>
<name><surname>Itoh</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Genetic background in patients with acute myocardial infarction</article-title>. <source>Jpn Heart J</source> <year>2001</year>; <volume>42</volume>: <fpage>15</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312447652">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ozisik</surname><given-names>K</given-names></name>
<name><surname>Misirlioglu</surname><given-names>M</given-names></name>
<name><surname>Ulus</surname><given-names>TA</given-names></name><etal/>
</person-group>. <article-title>Renin-angiotensin system polymorphisms and coronary artery surgery patients</article-title>. <source>Asian Cardiovasc Thorac Ann</source> <year>2005</year>; <volume>13</volume>: <fpage>153</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312447652">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andrikopoulos</surname><given-names>GK</given-names></name>
<name><surname>Richter</surname><given-names>DJ</given-names></name>
<name><surname>Needham</surname><given-names>EW</given-names></name><etal/>
</person-group>. <article-title>The paradoxical association of common polymorphisms of the renin-angiotensin system genes with risk of myocardial infarction</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2004</year>; <volume>11</volume>: <fpage>477</fpage>–<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312447652">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Araujo</surname><given-names>MA</given-names></name>
<name><surname>Menezes</surname><given-names>BS</given-names></name>
<name><surname>Lourenco</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>The A1166C polymorphism of the angiotensin II type-1 receptor in acute myocardial infarction</article-title>. <source>Arq Bras Cardiol</source> <year>2004</year>; <volume>83</volume>: <fpage>409</fpage>–<lpage>413</lpage>; <fpage>404</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr20-1470320312447652">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fan</surname><given-names>XH</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
<name><surname>Qiu</surname><given-names>CG</given-names></name><etal/>
</person-group>. <article-title>Analysis of the relationship between angiotensin 2 type 1 receptor gene polymorphism and the severity of coronary artery stenosis</article-title>. <source>J Zhengzhou University (Medical Sciences)</source> <year>2004</year>; <volume>39</volume>: <fpage>584</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr21-1470320312447652">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>CQ</given-names></name>
<name><surname>Liang</surname><given-names>T</given-names></name>
<name><surname>Zhou</surname><given-names>KY</given-names></name><etal/>
</person-group>. <article-title>Correlation between angiotensin II type 1 receptor gene A-C 1166 polymorphism and essential hypertension, coronary heart disease in Guangdong Hans</article-title>. <source>J Guangdong Medical College</source> <year>2001</year>; <volume>19</volume>: <fpage>406</fpage>–<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr22-1470320312447652">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jia</surname><given-names>YP</given-names></name>
<name><surname>Guo</surname><given-names>XH</given-names></name>
<name><surname>Lv</surname><given-names>JY</given-names></name><etal/>
</person-group>. <article-title>Relationship between angiotensin II type 1 receptor gene A1166/C polymorphism and coronary heart disease</article-title>. <source>Chinese J Integrative Medicine On Cardio-Cerebrovascular Disease</source> <year>2006</year>; <volume>4</volume>: <fpage>568</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312447652">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Xu</surname><given-names>W</given-names></name>
<name><surname>Yang</surname><given-names>CJ</given-names></name><etal/>
</person-group>. <article-title>Correlation between angiotensin II type 1 receptor gene A-C 1166 polymorphism and coronary heart disease in Chinese</article-title>. <source>Shan Dong Medicine</source> <year>2007</year>; <volume>47</volume>: <fpage>135</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312447652">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>R</given-names></name>
<name><surname>Chen</surname><given-names>YC</given-names></name>
<name><surname>Bai</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Association between angiotensin II type 1 receptor gene A →C polymorphism and coronary heart disease in Chinese</article-title>. <source>Journal of West China University of Medical Science</source>. <year>2002</year>; <volume>33</volume>: <fpage>533</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr25-1470320312447652">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>KX</given-names></name>
<name><surname>Liu</surname><given-names>TB</given-names></name>
<name><surname>Xu</surname><given-names>QX</given-names></name><etal/>
</person-group>. <article-title>Association of angiotensin II receptor type 1 gene single nucleotide polymorphism with Chinese essential hypertension complicated with coronary heart disease</article-title>. <source>Chin J Cardiol</source>. <year>2005</year>; <volume>33</volume>: <fpage>720</fpage>–<lpage>723</lpage>.</citation>
</ref>
<ref id="bibr26-1470320312447652">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>RZ</given-names></name>
<name><surname>Wang</surname><given-names>SY</given-names></name>
<name><surname>Dai</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Relationship between angiotensin 2 type 1 receptor gene A1166C polymorphism and coronary heart disease</article-title>. <source>Chinese Journal of Birth Health &amp; Heredity</source> <year>2004</year>; <volume>12</volume>: <fpage>26</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr27-1470320312447652">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yanping</surname><given-names>D</given-names></name>
</person-group>. <article-title>Analysis on angiotensin receptor polymorphism in high risk population with primary hypertension and coronary heart disease</article-title>. <source>J Henan Univ Sci Tech (Med Sci)</source> <year>2006</year>; <volume>24</volume>: <fpage>86</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr28-1470320312447652">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peng</surname><given-names>J</given-names></name>
<name><surname>Peng</surname><given-names>S</given-names></name>
<name><surname>Gong</surname><given-names>WX</given-names></name>
</person-group>. <article-title>Association between early-onset coronary heart disease and angiotensin II type 1 receptor gene polymorphism</article-title>. <source>Natl Med J China</source> <year>2002</year>; <volume>82</volume>: <fpage>471</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr29-1470320312447652">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakauchi</surname><given-names>Y</given-names></name>
<name><surname>Suehiro</surname><given-names>T</given-names></name>
<name><surname>Yamamoto</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease</article-title>. <source>Atherosclerosis</source> <year>1996</year>; <volume>125</volume>: <fpage>161</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr30-1470320312447652">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>RZ</given-names></name>
<name><surname>Wang</surname><given-names>SY</given-names></name>
<name><surname>Dai</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>ACE and AT1R gene polymorphisms and coronary artery disease</article-title>. <source>Chinese Journal of Cardiovascular Medicine</source> <year>2004</year>; <volume>9</volume>: <fpage>24</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr31-1470320312447652">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>CG</given-names></name>
<name><surname>Fan</surname><given-names>XH</given-names></name>
<name><surname>Fan</surname><given-names>HX</given-names></name><etal/>
</person-group>. <article-title>Association between angiotensin-converting enzyme and angiotensin 2 type 1 receptor gene polymorphism and the coronary heart disease</article-title>. <source>Molecular Cardiology of China</source> <year>2003</year>; <volume>3</volume>: <fpage>202</fpage>.</citation>
</ref>
<ref id="bibr32-1470320312447652">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jia</surname><given-names>YP</given-names></name>
<name><surname>Ren</surname><given-names>J</given-names></name>
<name><surname>Lv</surname><given-names>JY</given-names></name><etal/>
</person-group>. <article-title>The relationship between coronary heart disease and polymorphism of angiotensiongen and angiotensin II type 1 receptor genes</article-title>. <source>Chinese Journal of Cardiovascular Review</source> <year>2005</year>; <volume>3</volume>: <fpage>816</fpage>–<lpage>819</lpage>.</citation>
</ref>
<ref id="bibr33-1470320312447652">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname><given-names>XH</given-names></name>
<name><surname>Jia</surname><given-names>YP</given-names></name>
<name><surname>Lv</surname><given-names>JY</given-names></name><etal/>
</person-group>. <article-title>Association between angiotensin II type 1 receptor gene A1166/C polymorphism and coronary heart disease</article-title>. <source>Chinese Journal of Cardiovascular Review</source> <year>2006</year>; <volume>4</volume>: <fpage>498</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr34-1470320312447652">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>CG</given-names></name>
<name><surname>Fan</surname><given-names>XH</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Relation between coronary artery disease and polymorphism of type 1 angiotensin receptor and angiotensin-converting enzyme gene</article-title>. <source>Shan Dong Medicine</source> <year>2004</year>; <volume>44</volume>: <fpage>10</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr35-1470320312447652">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fan</surname><given-names>XH</given-names></name>
<name><surname>Fan</surname><given-names>HX</given-names></name>
<name><surname>Hu</surname><given-names>JQ</given-names></name><etal/>
</person-group>. <article-title>Relationship between angiotensin 2 type 1 receptor gene polymorphism and the risk factors of coronary heart disease</article-title>. <source>Molecular Cardiology of China</source> <year>2005</year>; <volume>5</volume>: <fpage>717</fpage>–<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr36-1470320312447652">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>C</given-names></name>
<name><surname>Han</surname><given-names>Z</given-names></name>
<name><surname>Lu</surname><given-names>W</given-names></name>
</person-group>. <article-title>Association of polymorphisms in angiotensin-converting enzyme and type 1 angiotensin II receptor genes with coronary heart disease and the severity of coronary artery stenosis</article-title>. <source>J Huazhong Univ Sci Technolog Med Sci</source> <year>2007</year>; <volume>27</volume>: <fpage>660</fpage>–<lpage>663</lpage>.</citation>
</ref>
<ref id="bibr37-1470320312447652">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>JP</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>: <fpage>1539</fpage>–<lpage>1558</lpage>.</citation>
</ref>
<ref id="bibr38-1470320312447652">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mantel</surname><given-names>N</given-names></name>
<name><surname>Haenszel</surname><given-names>W</given-names></name>
</person-group>. <article-title>Statistical aspects of the analysis of data from retrospective studies of disease</article-title>. <source>J Natl Cancer Inst</source> <year>1959</year>; <volume>22</volume>: <fpage>719</fpage>–<lpage>748</lpage>.</citation>
</ref>
<ref id="bibr39-1470320312447652">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DerSimonian</surname><given-names>R</given-names></name>
<name><surname>Laird</surname><given-names>N</given-names></name>
</person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <year>1986</year>; <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr40-1470320312447652">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Begg</surname><given-names>CB</given-names></name>
<name><surname>Mazumdar</surname><given-names>M</given-names></name>
</person-group>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <year>1994</year>; <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</citation>
</ref>
<ref id="bibr41-1470320312447652">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wa</surname><given-names>M</given-names></name>
<name><surname>Lin</surname><given-names>X</given-names></name>
<name><surname>Xia</surname><given-names>X</given-names></name>
</person-group>. <article-title>Relationship between angiotensin system gene polymorphisms and premature coronary artery disease</article-title>. <source>Clinical Medicine of China</source>. <year>2006</year>; <volume>22</volume>: <fpage>971</fpage>–<lpage>974</lpage>.</citation>
</ref>
<ref id="bibr42-1470320312447652">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>Y</given-names></name>
<name><surname>Nakamura</surname><given-names>N</given-names></name>
<name><surname>Inagami</surname><given-names>T</given-names></name>
</person-group>. <article-title>A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism</article-title>. <source>J Hypertens</source> <year>1997</year>; <volume>15</volume>: <fpage>703</fpage>–<lpage>714</lpage>.</citation>
</ref>
<ref id="bibr43-1470320312447652">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takayanagi</surname><given-names>R</given-names></name>
<name><surname>Ohnaka</surname><given-names>K</given-names></name>
<name><surname>Sakai</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor</article-title>. <source>Biochem Biophys Res Commun</source> <year>1992</year>; <volume>183</volume>: <fpage>910</fpage>–<lpage>916</lpage>.</citation>
</ref>
<ref id="bibr44-1470320312447652">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furuta</surname><given-names>H</given-names></name>
<name><surname>Guo</surname><given-names>DF</given-names></name>
<name><surname>Inagami</surname><given-names>T</given-names></name>
</person-group>. <article-title>Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor</article-title>. <source>Biochem Biophys Res Commun</source> <year>1992</year>; <volume>183</volume>: <fpage>8</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr45-1470320312447652">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ingelfinger</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease</article-title>. <source>Curr Opin Nephrol Hypertens</source> <year>2009</year>; <volume>18</volume>: <fpage>79</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr46-1470320312447652">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Iwao</surname><given-names>H</given-names></name>
</person-group>. <article-title>Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases</article-title>. <source>Pharmacol Rev</source> <year>2000</year>; <volume>52</volume>: <fpage>11</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr47-1470320312447652">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pendergrass</surname><given-names>KD</given-names></name>
<name><surname>Gwathmey</surname><given-names>TM</given-names></name>
<name><surname>Michalek</surname><given-names>RD</given-names></name><etal/>
</person-group>. <article-title>The angiotensin II-AT1 receptor stimulates reactive oxygen species within the cell nucleus</article-title>. <source>Biochem Biophys Res Commun</source> <year>2009</year>; <volume>384</volume>: <fpage>149</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr48-1470320312447652">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname><given-names>MM</given-names></name>
<name><surname>Buckenberger</surname><given-names>JA</given-names></name>
<name><surname>Jiang</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding</article-title>. <source>J Biol Chem</source> <year>2007</year>; <volume>282</volume>: <fpage>24262</fpage>–<lpage>24269</lpage>.</citation>
</ref>
<ref id="bibr49-1470320312447652">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Sun</surname><given-names>ML</given-names></name>
<name><surname>Peng</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Association of the angiotensin type 1 receptor gene A1166C polymorphisms with myocardial infarction: a meta-analysis</article-title>. <source>J Thromb Haemost</source> <year>2011</year>; <volume>9</volume>: <fpage>1258</fpage>–<lpage>1260</lpage>.</citation>
</ref>
<ref id="bibr50-1470320312447652">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>M</given-names></name>
<name><surname>Sham</surname><given-names>P</given-names></name>
<name><surname>Ye</surname><given-names>Z</given-names></name><etal/>
</person-group>. <article-title>A1166C genetic variation of the angiotensin II type I receptor gene and susceptibility to coronary heart disease: collaborative of 53 studies with 20,435 cases and 23,674 controls</article-title>. <source>Atherosclerosis</source> <year>2010</year>; <volume>213</volume>: <fpage>191</fpage>–<lpage>199</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>